LOS ANGELES, CA--(Marketwire - Jan 23, 2013) - The Michael Bass Group, an investment banking and strategic advisory services firm focused on healthcare information technology, healthcare IT services, healthcare mobility providers, medical technology and devices, today released a patent valuation report for MMR Global.
MMR Global (OTCQB: MMRF) with a current market cap of $10 million, provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The independent research report shows that the potential value of the patents in the U.S. domestic market could be worth in a range as low as $600 Million to a high of $1.1 Billion, or 100 times the current market cap of the company. In addition, MMR has many international patents as well that were not included in this evaluation.
According to a recent Press Release from the company, the Company now owns seven U.S. patents and has nearly 400 claims focused on the digital transmission of medical records, including Personal Health Records (PHRs). The Company also has additional U.S. patent applications pending, which include numerous continuation applications. Internationally, the Company has issued patents and pending applications in countries of commercial interest such as Australia, Singapore, New Zealand, Mexico, Canada, Hong Kong, Japan, South Korea, Israel, and European nations.
MMR has met with significant success in their early licensing efforts based on a five-plus year industry-wide awareness of the Company's intellectual property and its relevance to the market. In 2013, the Company will aggressively pursue infringement claims and plans on commencing litigation beginning this month against companies in healthcare, retail and other markets. The litigation just mentioned could potentially be key for a sharp appreciation in the stock price of MMR Global, as recent patent infringement plays have been red hot with traders and investors alike.
In addition, over the last month, MMR Global has entered into licensing agreements with EMR vendors, a laboratory reporting services vendor, a document management systems vendor providing services to more than 750 hospitals, and a Personal Health Record provider. They believe that this trend will continue which will provide a steady and ever increasing revenue stream to the company.
Based on government regulations and the breadth of its patent portfolio, MMR is well positioned to monetize its intellectual property given requirements under the law pertaining to HIPAA, the HITECH Act and Meaningful Use Stages 2 and 3. The Company believes hospitals, healthcare professionals and certain vendors responding to the current needs of the market will need licenses from the Company, or they could infringe upon MMR's portfolio of intellectual property.
Stay tuned for pending developments, as important catalysts may be set to occur in the days ahead.
A link to the Patent Valuation report is provided here:
As we cautioned in our previous article, MMR Global is a small company. While they did do revenues of around $1.5M for the past fiscal year and are forecasting revenues of over $5M this year, they are not cash flow positive as of yet and do have debt. Therefore any investment in these types of stocks does carry additional risk.
Contributor Adam Meadows' full report can be found here:
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com